Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Therapy (Monoclonal Antibodies)
"Antibody-Targeted Superantigens Are Potent Inducers of Tumor-Infiltrating T Lymphocytes In Vivo."
November 20th, 1995
According to the authors' abstract of an article published in Proceedings of the National Academy of Sciences of the United States of America, "Recruitment of antigen-specific tumor-infiltrating lymphocytes (TILs) is a major goal for immunotherapy of malignant tumors. We now describe that T-cell-activating superantigens targeted to a tumor by monoclonal antibodies induced large numbers of pseudospecific TILs and eradication of micrometastases. As a model for tumor micrometastases, syngeneic B16 melanoma cells transfected with the human colon carcinoma antigen C215 were injected intravenously into C57BL/6 mice and therapy with an anti-C215 Fab fragment-staphylococcal enterotoxin A...
Source: Cancer Weekly (1995-11-20)
|
|
Advertisement |
|
|
